MAPT and Alzheimer disease: Pre-clinical models have shown that 5-LOX over-expression in transgenic AD mice leads to tau hyperphosphorylation, while 5-LOX inhibition reduces tau phosphorylation pointing to its contribution to the pathology (Chu and Praticò, 2011; Chu et al., 2013).